secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001213900-25-004873
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INM-901 shows statistically significant reduction in neuroinflammation in long-term Alzheimer's model
--------------------------------------------------------------------------------

- INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.
- High dose group showed statistically significant reduction in neurodegeneration biomarker NfL in plasma.
- mRNA data showed reduction of neuroinflammatory genes GFAP, CD-33, TLR-2 in brain, supporting study results.
- Company will complete analyses of receptor engagement, neuritogenesis, and neuroprotection in coming weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/0001213900-25-004873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/ea0228190-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-004873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer